Skip to content
10-Q

Quarterly Report

MEREO BIOPHARMA GROUP PLC MREO

0001193125-25-274272

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 10, 2025 795.66M sh
Shares Diluted Q3 2025 · Sep 30, 2025 799.95M sh
Shares Diluted Q3 2025 · Sep 30, 2025 796.02M sh
Shares Diluted Q3 2025 · Sep 30, 2024 770.15M sh
Shares Diluted Q3 2025 · Sep 30, 2024 727.81M sh
Shares Diluted Q3 2025 · Jun 30, 2024 770.15M sh
Capex Q3 2025 · Sep 30, 2025 $20K
Capex Q3 2025 · Sep 30, 2024 $0
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$23.29M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$23.41M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $48.7M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $69.8M
Stockholders Equity Q3 2025 · Sep 30, 2025 $46.6M
Stockholders Equity Q3 2025 · Jun 30, 2025 $54.18M
Stockholders Equity Q3 2025 · Mar 31, 2025 $60.08M
Stockholders Equity Q3 2025 · Dec 31, 2024 $60.97M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 −$72.54M
Stockholders Equity Q3 2025 · Jun 30, 2024 $78.65M
Stockholders Equity Q3 2025 · Mar 31, 2024 $42.84M
Stockholders Equity Q3 2025 · Dec 31, 2023 $50.54M
Current Liabilities Q3 2025 · Sep 30, 2025 $6.02M
Current Liabilities Q3 2025 · Dec 31, 2024 $13.85M
Total Liabilities Q3 2025 · Sep 30, 2025 $7M
Total Liabilities Q3 2025 · Dec 31, 2024 $15.42M
Current Assets Q3 2025 · Sep 30, 2025 $52.41M
Current Assets Q3 2025 · Dec 31, 2024 $74.76M
Total Assets Q3 2025 · Sep 30, 2025 $53.6M
Total Assets Q3 2025 · Dec 31, 2024 $76.39M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.01
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.04
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.02
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.05
Eps Diluted Q3 2025 · Jun 30, 2024 −$0.02
Eps Basic Q3 2025 · Sep 30, 2025 −$0.01
Eps Basic Q3 2025 · Sep 30, 2025 −$0.04
Eps Basic Q3 2025 · Sep 30, 2024 −$0.02
Eps Basic Q3 2025 · Sep 30, 2024 −$0.05
Eps Basic Q3 2025 · Jun 30, 2024 −$0.02
Sga Expense Q3 2025 · Sep 30, 2025 $6.05M
Sga Expense Q3 2025 · Sep 30, 2025 $18.81M
Sga Expense Q3 2025 · Sep 30, 2024 $6.2M
Sga Expense Q3 2025 · Sep 30, 2024 $19.98M
Rd Expense Q3 2025 · Sep 30, 2025 $4.27M
Rd Expense Q3 2025 · Sep 30, 2025 $13.57M
Rd Expense Q3 2025 · Sep 30, 2024 $3.17M
Rd Expense Q3 2025 · Sep 30, 2024 $12.11M
Net Income Q3 2025 · Sep 30, 2025 −$7.02M
Net Income Q3 2025 · Sep 30, 2025 −$34.53M
Net Income Q3 2025 · Jun 30, 2025 −$14.62M
Net Income Q3 2025 · Mar 31, 2025 −$12.89M
Net Income Q3 2025 · Sep 30, 2024 −$15M
Net Income Q3 2025 · Sep 30, 2024 −$36.21M
Net Income Q3 2025 · Jun 30, 2024 −$12.26M
Net Income Q3 2025 · Mar 31, 2024 −$8.95M
Operating Income Q3 2025 · Sep 30, 2025 −$10.02M
Operating Income Q3 2025 · Sep 30, 2025 −$31.72M
Operating Income Q3 2025 · Sep 30, 2024 −$9.37M
Operating Income Q3 2025 · Sep 30, 2024 −$32.09M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $500K
Revenue Q3 2025 · Sep 30, 2024 $0
Revenue Q3 2025 · Sep 30, 2024 $0
Stock Issued Q3 2025 · Feb 28, 2025 17.11M sh